The Great Acquirer Strikes Again

In this video, health-care analyst David Williamson discusses Valeant's latest acquisition target. Although this is no bite-sized morsel, generic-drug maker Actavis would be a potentially transformative merger of equals. 

The deal appears to have hit a snag, and that could be the best outcome for investors in both companies. Valeant probably wouldn't offer Actavis investors much of a premium, and Valeant investors excited about small, accretive deals in the brande-drug space would be in for a rude awakening.  Watch and find out why.

What macro trend was Warren Buffett referring to when he said "this is the tapeworm that's eating at American competitiveness"? Find out in our free report: "What's Really Eating at America's Competitiveness." You'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2398923, ~/Articles/ArticleHandler.aspx, 10/25/2014 1:40:31 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 4 hours ago Sponsored by:
DOW 16,805.41 127.51 0.76%
S&P 500 1,964.58 13.76 0.71%
NASD 4,483.72 30.92 0.69%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/24/2014 4:01 PM
VRX $129.13 Up +1.11 +0.87%
Valeant Pharmaceut… CAPS Rating: ***
ACT $240.33 Up +3.12 +1.32%
ACTAVIS CAPS Rating: ***
OMPI.DL $0.00 Down +0.00 +0.00%
Obagi Medical Prod… CAPS Rating: ***

Advertisement